Cargando…

Quadruple and Truncated MEK3 Mutants Identified from Acute Lymphoblastic Leukemia Promote Degradation and Enhance Proliferation

Compared to other ethnicities, Hispanic children incur the highest rates of leukemia, and most cases are diagnosed as Acute Lymphoblastic Leukemia (ALL). Despite improved treatment and survival for ALL, disproportionate health outcomes in Hispanics persist. Thus, it is essential to identify oncogeni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ayala-Marin, Yoshira M., Grant, Alice H., Rodriguez, Georgialina, Kirken, Robert A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8618549/ https://www.ncbi.nlm.nih.gov/pubmed/34830095 http://dx.doi.org/10.3390/ijms222212210

Ejemplares similares

Phosphorylation of CrkL S114 induced by common gamma chain cytokines and T-cell receptor signal transduction
por: Estrada, Armando, et al.
Publicado: (2021)

The Genomic Landscape of a Restricted ALL Cohort from Patients Residing on the U.S./Mexico Border
por: Grant, Alice Hernandez, et al.
Publicado: (2021)

The Many Faces of JAKs and STATs Within the COVID-19 Storm
por: Grant, Alice H., et al.
Publicado: (2021)

JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling
por: Grant, Alice H., et al.
Publicado: (2023)

MEK Inhibitors Potentiate Dexamethasone Lethality in Acute Lymphoblastic Leukemia Cells through the Pro-apoptotic Molecule BIM
por: Rambal, Anila A., et al.
Publicado: (2009)

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S, et al.
Publicado: (2018)

Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting
por: Knight, Thomas, et al.
Publicado: (2014)

Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
por: Degryse, S., et al.
Publicado: (2018)

Phosphoflow-Based Evaluation of Mek Inhibitors as Small-Molecule Therapeutics for B-Cell Precursor Acute Lymphoblastic Leukemia
por: George, Aswathi A., et al.
Publicado: (2015)

BIM mediates synergistic killing of B-cell acute lymphoblastic leukemia cells by BCL-2 and MEK inhibitors
por: Korfi, K, et al.
Publicado: (2016)

Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia
por: Demir, Salih, et al.
Publicado: (2020)

MEK inhibitors for the treatment of NRAS mutant melanoma
por: Sarkisian, Saro, et al.
Publicado: (2018)

Quadruple Pregnancy
por: Arthur, M.
Publicado: (1885)

FAM53B truncation caused by t(10;19)(q26;q13) chromosome translocation in acute lymphoblastic leukemia
por: Panagopoulos, Ioannis, et al.
Publicado: (2017)

Correction: Genome Wide Mapping Reveals PDE4B as an IL-2 Induced STAT5 Target Gene in Activated Human PBMCs and Lymphoid Cancer Cells
por: Nagy, Zsuzsanna S., et al.
Publicado: (2013)

Genome Wide Mapping Reveals PDE4B as an IL-2 Induced STAT5 Target Gene in Activated Human PBMCs and Lymphoid Cancer Cells
por: Nagy, Zsuzsanna S., et al.
Publicado: (2013)

CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition
por: Meyer, Lauren K., et al.
Publicado: (2019)

MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations
por: Kerstjens, Mark, et al.
Publicado: (2016)

Over-expressed, N-terminally truncated BRAF is detected in the nucleus of cells with nuclear phosphorylated MEK and ERK
por: Hey, Fiona, et al.
Publicado: (2018)

Sensitivity of imatinib-resistant T315I BCR-ABL CML to a synergistic combination of ponatinib and forskolin treatment
por: Oaxaca, Derrick M., et al.
Publicado: (2016)

Mutant IL7R collaborates with MYC to induce T-cell acute lymphoblastic leukemia
por: Oliveira, Mariana L., et al.
Publicado: (2022)

NET1 Enhances Proliferation and Chemoresistance in Acute Lymphoblastic Leukemia Cells
por: Sun, Hongbo, et al.
Publicado: (2019)

MEK and PI3K-AKT inhibitors synergistically block activated IL7 receptor signaling in T-cell acute lymphoblastic leukemia
por: Canté-Barrett, K, et al.
Publicado: (2016)

P349: CRISPR/CAS9 SCREEN IDENTIFIES PTPMT1 AS AN ESSENTIAL GENE FOR ACUTE LYMPHOBLASTIC LEUKEMIA PROLIFERATION
por: LI, Jiazheng, et al.
Publicado: (2023)

Rapid Shift from SARS-CoV-2 Delta to Omicron Sub-Variants within a Dynamic Southern U.S. Borderplex
por: Robles-Escajeda, Elisa, et al.
Publicado: (2023)

Triple and quadruple jets
por: Kunszt, Zoltán
Publicado: (1984)

Case of Quadruple Birth
por: Wilson, James
Publicado: (1866)

Potent Sensitisation of Cancer Cells to Anticancer Drugs by a Quadruple Mutant of the Human Deoxycytidine Kinase
por: Coulibaly, Safiatou T., et al.
Publicado: (2015)

An attenuated quadruple gene mutant of Mycobacterium tuberculosis imparts protection against tuberculosis in guinea pigs
por: Bahal, Ritika Kar, et al.
Publicado: (2017)

Ion Homeostasis and Metabolome Analysis of Arabidopsis 14-3-3 Quadruple Mutants to Salt Stress
por: Gao, Jing, et al.
Publicado: (2021)

CSF3R truncation mutations in a patient with B-cell acute lymphoblastic leukemia and a favorable response to chemotherapy plus dasatinib
por: Schwartz, Marc S., et al.
Publicado: (2020)

Inhibition of the NEDD8 conjugation pathway induces calcium-dependent compensatory activation of the pro-survival MEK/ERK pathway in acute lymphoblastic leukemia
por: Zheng, Shuhua, et al.
Publicado: (2017)

CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in Ras pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response
por: Dixon, Zach A., et al.
Publicado: (2017)

JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
por: Kim, Sang-Kyu, et al.
Publicado: (2018)

Clonal evolution mechanisms in NT5C2 mutant relapsed acute lymphoblastic leukemia
por: Tzoneva, Gannie, et al.
Publicado: (2018)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
por: Atefi, Mohammad, et al.
Publicado: (2015)

Mutant HRAS as novel target for MEK and mTOR inhibitors
por: Kiessling, Michael K., et al.
Publicado: (2015)

MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia
por: Morales, María Luz, et al.
Publicado: (2019)

A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC
por: Dompe, Nicholas, et al.
Publicado: (2018)

Phosphorylation of Tyrosine 841 Plays a Significant Role in JAK3 Activation
por: Sun, Shengjie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r1el16dc8m4aasmmb8siiiofeb